MCK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
McKesson is not a strong buy right now for a beginner long-term investor, but it is also not a clear sell. At the current pre-market price of 792.41, the stock is trading near short-term resistance and above its pivot, with positive momentum but mixed confirmation. Because the user is impatient and wants a direct decision, my view is to hold off on buying today and wait for a better entry or stronger confirmation. The stock's long-term business remains solid, but current signals are not compelling enough to justify an immediate purchase at this level.
The technical setup is mixed-to-bullish. MACD histogram is strongly positive at 8.237 and expanding, which supports upward momentum. However, RSI_6 is 69.155, which is close to overbought territory and suggests the stock is extended in the short term. Moving averages are converging, showing the trend is not fully decisive. Price is currently near resistance at R1 790.86, just above the pre-market price of 792.41, with the pivot at 763.673 providing support below. Overall, the trend is constructive but stretched, making this a weaker immediate entry for a beginner long-term buyer.
Recent analyst commentary remains broadly constructive, with multiple firms keeping Buy or Outperform ratings. UBS raised its target to 1,050 and said the FY27 outlook looked good enough despite a messy Q4 print. BofA noted FY27 guidance and the long-range plan were clear positives. William Blair initiated with Outperform, citing a durable moat and specialty-led growth upside. The stock also benefits from a favorable healthcare distribution and specialty medicines backdrop.
Several firms lowered price targets recently, including Citi, Deutsche Bank, Baird, JPMorgan, Evercore ISI, BofA, and UBS, which shows sentiment is positive but less enthusiastic than before. Insider selling has increased 144.45% over the last month, which is a negative signal. Congress trading data also shows 1 sale and 0 purchases in the last 90 days, indicating cautious political positioning. The latest market news is risk-off overall due to geopolitical and rate concerns, which may limit upside in the near term. Similar candlestick pattern analysis suggests a negative short-term drift over the next day, week, and month.
No financial snapshot data was usable because of the error provided, so I cannot assess the latest quarter fundamentals in detail. Based on the analyst commentary, the company likely delivered a mixed recent quarter, with investors focusing more on FY27 guidance and the long-range plan than on the immediate print. The latest quarter season appears to have been a mixed Q4/Q1 period, with management guidance viewed more positively than the reported results.
Analyst sentiment is still positive overall, with Buy/Outperform/Overweight ratings maintained across major firms, but price targets have mostly been cut in recent updates. This suggests Wall Street still likes the stock's long-term quality, yet expectations have been reset lower after a mixed quarter. The pros view is durable moat, specialty growth, demographic tailwinds, and clear guidance support. The cons view is valuation pressure, softer near-term enthusiasm, and reduced price targets across multiple firms. Overall, analysts remain constructive, but the trend in target revisions is negative.
